APA

Heitz F., Harter P., Åvall-Lundqvist E., Reuss A., Pautier P., Cormio G., Colombo N., Reinthaller A., Vergote I., Poveda A., Ottevanger P. B., Hanker L. C., Leminen A., Alexandre J., Canzler U., Sehouli J., Herrstedt J., Fiane B., Merger M. & du Bois A. (20190221). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. : Gynecologic oncology.

Chicago

Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger P B, Hanker L C, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M and du Bois A. 20190221. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. : Gynecologic oncology.

Harvard

Heitz F., Harter P., Åvall-Lundqvist E., Reuss A., Pautier P., Cormio G., Colombo N., Reinthaller A., Vergote I., Poveda A., Ottevanger P. B., Hanker L. C., Leminen A., Alexandre J., Canzler U., Sehouli J., Herrstedt J., Fiane B., Merger M. and du Bois A. (20190221). Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. : Gynecologic oncology.

MLA

Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger P B, Hanker L C, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M and du Bois A. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. : Gynecologic oncology. 20190221.